Modular Medical, Inc.MODD

Modular Medical, Inc. lost $28.2 million in the year ended 31 March 2026, according to the freshly filed 10-K, while its balance sheet showed $6.9 million of cash and $13 million of shareholders’ equity against $1.9 million of liabilities. The company’s operating activities consumed $23.8 million in cash, R&D chewed through another $20 million, and capex on factory hardware ate $3.9 million-all while the diluted loss per share landed at $12.36.

Modular Medical sells the MODD1 insulin-delivery system via three kits-Starter, Pump Refill, and Monthly Supply-marketed as a simpler alternative to manual injections on its official patient page. The device itself is presented as a sleek, single-pump solution, but the company’s public filings do not reveal any revenue, gross margin, or customer count, leaving investors to estimate performance from the cash-burn ledger rather than sales ledgers. The firm’s investor relations site confirms that no dividends have ever been paid and that any future earnings will be reinvested to fund growth, a polite way of saying the current model is not yet self-funding.

The SEC filings between March and July 2026 show Modular Medical’s common stock is tradable through any broker, but the ownership XML reveals a thin float with insiders holding single-digit percentages. The company’s website continues to feature product imagery and patient stories, yet the only concrete data in the evidence set are the red-ink numbers from the 10-K: net loss, operating loss, and the twelve-figure loss per share. There is no revenue line, no order backlog, and no approval milestone in the sourced evidence.

For a stock touted as a diabetes-device innovator, the public rail provides The source-change rail is filing/source-led and does not use chart-derived signals. Chart context is available separately on this page through the Atlas chart snapshot or TradingView route where available. The company’s own pages market hope; the filings report arithmetic. (source: SEC EDGAR filings index, https://www.sec.gov/edgar/browse/?CIK=1074871)

What changed this week? The SEC EDGAR index added Modular Medical’s 10-K for the year to 31 March 2026 on 2 July 2026, and the ownership XML was updated the same day-both events are publicly timestamped but contain no new financial metrics or product approvals. The company’s product and patient pages remain unchanged in the evidence set, and the investor site reiterates the no-dividend, all-reinvestment policy without supplying any forward-looking revenue or cash guidance. In short, the filing rail deepened while the operating rail stayed static.

What remains unproven? Revenue, gross margin, customer numbers, payer coverage, FDA approval milestones for MODD1, and any timeline for profitability are all absent from the evidence provided to the public. The filings confirm cash burn and equity erosion; they do not confirm product uptake, regulatory clearance, or commercial traction. Until those datapoints appear, the stock’s narrative is built on narrative rather than numbers.